西宁高血压模型(江苏静脉穿刺虚拟训练系统) (今日更新中)

SUVA, Jan. 21 (Xinhua) -- Three in four people of the Fiji population are physically inactive causing an increase in health risks, says the country's Ministry of Health.National Advisor on Non-Communicable Disease Dr. Isimeli Tukana said that lifestyle in this Fijian generation has changed a lot, especially for the younger population that have been influenced by technology.Tukana said on Friday many children nowadays are obese and that was of growing concern. That is why the Ministry of Health is working with the Ministry of Education in promoting more physical education in schools and making it compulsory from this school term.Fiji was recently ranked the fourth-most obese nation in the region, according to the Health Ministry.Recent studies in Fiji showed a high incidence of anaemia in children, women and men.Figures released by the ministry said more than 60 percent of the island nation's population is overweight while a significant number are deficient in iron and micronutrients.The figures show that the high rate of premature disability with Non Communicable Diseases (NCD), infection and cancer has taken its toll on the population."The importance of our traditional diets, healthy eating and physical activities is paramount," a ministry statement had said."In the Pacific NCDs have reached epidemic proportions," it said."Nutritional imbalances resulting from not eating local produce instead of canned, processed food contribute to the equation, especially in these times of global economic crisis."Women's Minister Dr. Jiko Luveni has advised mothers in the country this week to stock up on healthy foods for their families.She said having green leafy vegetables was vital and buying fruits for children's snacks instead of salted prepacked ones was the way to keep the family healthy.The National Food and Nutrition Council said Friday that as the school year draws parents should find healthy alternatives for their children.They have urged teachers and parents to include fruits in every child's meal to reduce NCDs.In other countries in the region Tokelau and Nauru's obesity rates stand at 93 percent to 93.5 percent of the population.In American Samoa and Kiribati obesity stands at 81.5 percent of the population, while Marshall Islands at 80.1 percent, Federated States of Micronesia (Pohnpei) at 73.1 percent.

WASHINGTON, Oct. 18 (Xinhua) -- Scientists have increased the estimate of the number of humpback whales in the North Pacific Ocean, according to a paper published Tuesday in the Marine Mammal Science journal.The increase follows a refined statistical analysis of data compiled in 2008 from the largest whale survey ever carried out to appraise humpback whale populations throughout the North Pacific.The number of North Pacific humpback whales in the 2008 study, known as the Structure of Populations, Levels of Abundance and Status of Humpbacks, or SPLASH, was estimated at just under 20,000 based on a preliminary look at the data.The latest research indicates the population to be over 21,000 and possibly even higher -- a significant improvement to the scant 1,400 humpback whales estimated in the North Pacific Ocean at the end of commercial whaling in 1966."These improved numbers are encouraging, especially after we have reduced most of the biases inherent in any statistical model," said Jay Barlow, marine mammal biologist of the U.S. National Oceanic and Atmospheric Administration (NOAA)."We feel the numbers may even be larger since there have been across-the-board increases in known population areas and unknown areas have probably seen the same increases," Barlow added.The SPLASH research was a three-year project started in 2004 involving NOAA scientists and hundreds of other researchers from the United States, Japan, Russia and some other countries.It was the first systematic survey ever attempted to determine the humpback whales' overall population, structure and genetic makeup in the North Pacific.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

SHANGHAI, Jan. 11 (Xinhua) -- China has allowed the Bank of East Asia (BEA) to issue yuan-denominated bonds in Hong Kong for a second time, about three years after it became the first foreign-invested bank to make a yuan bond issuance, the bank said Wednesday.BEA China Ltd, a wholly-owned subsidiary of the BEA, was given the approval by the National Development and Reform Commission of China to issue yuan bonds in Hong Kong, it said.Details on the amounts and timing of the offerings weren't available. In 2009, in a major landmark, the BEA issued its first yuan bonds in Hong Kong in an aggregate principal amount of 4 billion yuan (630 million U.S. dollars).The BEA was among the first foreign-invested banks to be given the green light to issue yuan-denominated bonds in Hong Kong, a move analysts say will bolster the international influence of the Chinese currency, also known as renminbi.Sun Minjie, deputy head of BEA China, said the second bond issuance will give the bank stable access to capital, improve its debt portfolio, and support its development on the Chinese mainland.

来源：资阳报